You are here

Our science / Clinical Trials / Find a Trial / NCT01243138

Africa and Middle East Cardiovascular Epidemiological Study

Back to Search Print Save as PDF Bookmark Trial

NCT01243138

Last updated on April 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Alger, , 16015 Algeria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity, Smoking, Dyslipidemia, Diabetes Mellitus, Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult aged 18 or above

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant women and/or lactating mothers

- Subjects presenting with any life threatening disease/condition

NCT01243138
Pfizer
Completed
Africa and Middle East Cardiovascular Epidemiological Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Familial Persistent Pulmonary Hypertension
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
NCT01720524
All Genders
0+
Years
Multiple Sites
Hypertension
Amlodipine 10mg Drug Use Investigation
NCT01252563
All Genders
Hypertension
A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population
NCT00930722
All Genders
18+
Years
Multiple Sites
Hypertension
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
NCT00796159
All Genders
Africa and Middle East Cardiovascular Epidemiological Study
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.

Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Observational
Time Perspective: Cross-Sectional
Not Provided
Retention:   None Retained
Description:
Whole Blood
Probability Sample
Subject selection would be from clinics in a primary care setting
  • Obesity
  • Smoking
  • Dyslipidemia
  • Diabetes Mellitus
  • Hypertension
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4386
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult aged 18 or above

Exclusion Criteria:

  • Pregnant women and/or lactating mothers
  • Subjects presenting with any life threatening disease/condition
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Algeria,   Cameroon,   Egypt,   Ghana,   Jordan,   Kenya,   Kuwait,   Lebanon,   Nigeria,   Saudi Arabia,   Senegal,   South Africa,   Tunisia,   United Arab Emirates
 
 
NCT01243138
A2581186
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now